Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma.

Fiche publication

Date publication

avril 2023

Journal

Journal of gastrointestinal oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie , Pr GHIRINGHELLI François , Pr LEPAGE Côme , Dr VINCENT Julie , Pr MANFREDI Sylvain , Dr BENGRINE-LEFEVRE Leila , Dr HENNEQUIN Audrey

Tous les auteurs :
Piquemal D, Bruno R, Bournet B, Ghiringhelli F, Noguier F, Canivet C, Bertaut A, Pierrat F, Evesque L, Gamez A, Cros J, Rederstorff E, Petit E, Adnet J, Saint A, Drouillard A, Kempf E, Soularue E, Vincent J, Baumgaertner I, Hennequin A, Tournigand C, Lopez Trabada Ataz D, Bengrine L, Lepage C, Manfredi S, Afchain P, Trouilloud I, Gagnaire A, LoConte NK, Bachet JB

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37201091

Résumé

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, and chemotherapy is a key treatment for advanced PDAC. Gemcitabine chemotherapy is still an important component of treatment; however, there is no routine biomarker to predict its efficacy. Predictive tests may help clinicians to decide on the best first-line chemotherapy.